Clinical trials: Cardiac Transplant Rejection
Heart Transplant Rejection
Cardiac Transplant Metabolomics With and Without Rejection
Patient who received a heart transplant may develop organ rejection. Currently, an invasive biopsy of the heart needs to be performed to diagnose rejection.
- Trial name
- ANTIPARTICLE (NCT05772442)
- Testing
- Extra blood samples (5-10 mL) drawn
- Volunteers
- 100 people
- Sponsor
- Western University, Canada
Heart Transplant Rejection
Molecular Diagnosis of Heart Allograft Rejection Using Intra-Graft Targeted Gene Expression Profiling.
The goal of this observational study is to develop and validate a molecular heart rejection diagnostic system based on targeted transcriptome as a novel monitoring companion tool for heart allograft precision diagnostics…
- Trial name
- Nano-Heart (NCT06436027)
- Testing
- Nano-Heart tool: Intra-Graft Targeted Gene Expression Profiling
- Where
- 3 sites in United States, France and 1 more
- Volunteers
- 496 people
- Sponsor
- Paris Translational Research Center for Organ Transplantation
Cardiac Transplantation
Absolute Myocardial Perfusion Measurement in the Transplanted Heart
The goal of this study is to detect AR and CR in the transplanted heart by quantitative assessment of myocardial blood flow and its constituents by myocardial contrast echocardiography (MCE).
- Trial name
- NCT00414895
- Where
- Switzerland
- Volunteers
- 90 people
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Heart Transplant Rejection, Heart Transplant Infection
TTV Viral Load in Heart Transplant Recipients
This prospective, multicenter, non-interventional trial aims to study the association between TTV viral load and the occurrence of rejection or infection during the first year after transplantation.
- Conditions
- Heart Transplant Rejection, Heart Transplant Infection, Virus
- Trial name
- TTVCoeur (NCT05064462)
- Testing
- Collection of EDTA blood sample (5 to 7 ml)
- Where
- 3 sites in France
- Volunteers
- 60 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Failure, Respiratory Failure
Donor Simvastatin Treatment in Organ Transplantation
The aim of the study is to investigate the effects of donor simvastatin treatment on ischemia-reperfusion injury after heart transplantation.
- Conditions
- Heart Failure, Respiratory Failure, Liver Failure, Kidney Failure
- Trial name
- SIMVA (NCT01160978)
- Testing
- Simvastatin 80mg, Control Rx
- Where
- Finland
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital
Heart Transplant Rejection, Graft Failure
Phase II Study Evaluating the Efficacy of Tacrolimus Extended Release Tablets to Twice Daily Tacrolimus Dosing Regimen
This phase II, single-center, open-label study will evaluate the comparable efficacy of tacrolimus extended release tablets (Envarsus®) to the standard of care (SOC) twice daily tacrolimus (Prograf®) dosing regimen post-cardiac…
- Conditions
- Heart Transplant Rejection, Graft Failure, Compliance, Patient
- Trial name
- Veloxis (NCT03373227)
- Testing
- Envarsus
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Baylor Research Institute
Heart Transplant Rejection
Trifecta-Heart cfDNA-MMDx Study
Demonstrate the relationship between DD-cfDNA levels and HLA antibodies in blood transplant recipient and the Molecular Microscope® (MMDx) Diagnostic System results in indication and protocol biopsies from heart transplants.
- Trial name
- NCT04707872
- Testing
- MMDx diagnostic test, Prospera, HLA antibody
- Where
- 12 sites in United States, Australia and 5 more
- Volunteers
- 300 people
- Sponsor
- University of Alberta
Cardiac Transplant Rejection, Qt Interval, Variation in
Home Electrocardiogram (ECG) Monitoring After Heart Transplantation
The long-term goal of this research is to apply novel technology for detection of donor organ (allograft) rejection to improve patient outcomes following heart transplantation.
- Trial name
- NEW HEART (NCT01365806)
- Where
- 3 sites in United States
- Volunteers
- 345 people
- Sponsor
- University of California, Los Angeles
Heart Transplantation
A Study of CellCept (Mycophenolate Mofetil) in Combination Therapy in Heart Transplant Patients.
This study will investigate the efficacy and safety of CellCept (1.5-2g/day po), in combination with a standard care regimen of cyclosporine A (trough level 150-200ng/mL) and steroids, in patients receiving a heart transplant.
- Trial name
- NCT02091414
- Testing
- mycophenolate mofetil (MMF), cyclosporine A (CsA), corticosteroids
- Where
- 3 sites in China
- Volunteers
- 36 people
- Sponsor
- Hoffmann-La Roche
Cardiac Allograft Vasculopathy, Heart Transplant Rejection
Extracorporeal Photopheresis and Early Cardiac Graft Vasculopathy
Heart transplantation is a golden standard for the treatment of terminal heart failure. The major cause of death in late posttransplant period is cardiac allograft vasculopathy (CAV).
- Trial name
- ECP-OCT (NCT04226521)
- Testing
- Extracoropreal photopheresis
- Where
- Croatia
- Volunteers
- 38 people
- Sponsor
- Bosko Skoric
Heart Transplant Failure
Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes
Heart transplant is the only effective treatment for people with advanced heart failure. Post-transplant pharmacological therapies are of fundamental importance for the survival of individuals after surgery: although considerable…
- Trial name
- NCT06338306
- Testing
- Tacrolimus（FK506）
- Where
- Italy
- Volunteers
- 25 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Heart Transplantation
Superiority Assessment of Donor-derived Cell-FreE DNA ( Deoxyribonucleic Acid) for Cardiac Allograft REjection Monitoring
Heart transplantation (HTx) remains the gold-standard treatment for patients with end-stage heart failure refractory to the medical management, offering the best survival and quality of life.
- Trial name
- SAFE-CARE (NCT07897526)
- Testing
- non-invasive strategy based of the analysis of circulating dd-cfDNA (AlloSeq cfDNA assay), control
- Volunteers
- 352 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Heart Transplant Rejection
Biomarkers for Diagnosis, Prognosis, and Targeted Therapy After Heart Transplantation
The objective of this prospective observational single center study is to investigate donor-derived cell-free DNA (ddcfDNA), peripheral blood platelet mRNA, peripheral blood extracellular vesicle mRNA, and peripheral blood…
- Trial name
- EMBIO (NCT06064123)
- Testing
- Cell-free DNA
- Where
- Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Helsinki University Central Hospital